Germany remains one of the most attractive and most procedurally demanding countries in Europe to run a clinical trial.
It possesses strong site experience and reputable academic medical centers, along with a stringent regulatory system that does not compromise on standards. This can pose challenges for sponsors assuming that EU submissions will proceed as smoothly in Germany as in less regulated member states. Understanding the approval processes, practical GCP compliance, and common bottlenecks is crucial for trial sponsors, whether planning a new trial or facing inspections in existing ones.
Two Authorities, One Ethics Committee
Germany regulates medicinal products and vaccines separately through the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and the Paul-Ehrlich-Institut (PEI), respectively. Conducting trials requires simultaneous approval from both the competent authority and the ethics committee, as neither can substitute for the other.
Since January 2023, all initial clinical trial applications in the European Economic Area, including Germany, must utilize the Clinical Trials Information System (CTIS), replacing the previous EudraCT-based process. This transition has led to challenges for sponsors accustomed to the earlier workflow, particularly due to CTIS’s requirement for a specific document structure. Frequent causes of validation delays include incomplete national annexes and missing German-language translations.
Timeline for the application
In Germany, the national validation check usually takes 10 to 21 days, during which the BfArM or PEI confirms the completeness of the application parts. The ethics committee also verifies receipt of necessary materials. A key aspect is the clock-stop mechanism; if validation queries arise, the review clock halts until the sponsor satisfactorily responds. Minor issues require replies within 7 to 14 days, while major queries can take 21 to 30 days, adding to timeline uncertainty. To safeguard timelines, submitting a complete application is more effective than submitting early.
Worth watching for 2026: European regulators and ethics committees have agreed to pilot FAST-EU, a fast-track approach for authorizing multinational trials starting January 2026. This initiative aims for quicker, more predictable approvals while maintaining scientific, ethical, and safety standards. BfArM and PEI are active contributors and sponsors with multinational programs involving Germany and should monitor this pilot, as it may alter timeline expectations for qualifying trials.
Overview of GCP in Germany
Good Clinical Practice in Germany aligns with EU regulations and national laws, including the German Medicinal Products Act and GCP Ordinance, as well as ICH-GCP standards and the Declaration of Helsinki. GCP compliance encompasses key aspects of clinical trials, such as informed consent, investigator qualifications, protocol adherence, and adverse event reporting, ensuring participant rights and data integrity. Treating GCP merely as a compliance requirement is a mistake in Germany, as inspections by the GCP Inspections Unit emphasize the importance of both participant safety and scientific validity.
GCP inspection in Germany’s clinical trials
BfArM’s GCP Inspections Unit ensures compliance in clinical trials, adhering to EU regulations and the AMG. Inspections follow guidelines from the GCP Inspectors Working Group, with results recognized across EU member states, meaning shortcomings in Germany affect trial data in other jurisdictions.
Inspections are categorized as pre-approval and post-approval. Pre-approval inspections review trial data validity before marketing authorization, ensuring compliance with ethical standards. Post-approval inspections occur after authorization, usually triggered by specific concerns or routine checks. Inspectors analyze comprehensive documentation, including source documents and consent records, to validate trial conduct. For sponsors, maintaining a contemporaneous documentation trail is crucial, as retrospective reconstruction often fails to withstand scrutiny.
- Incomplete national documentation, specifically regarding German-language translation requirements and national annex completeness, often leads to avoidable delays. A dossier compliant with one EU member state may not be suitable for submission in Germany.
- Underestimating the dual-approval structure can cause issues, as sponsors often view the ethics committee opinion as merely formal and assume it will align with the competent authority’s satisfaction. In Germany, both tracks operate concurrently and are equally significant, so they require attention in the submission timeline.
- Weak delegation and inadequate consent documentation are critical areas often scrutinized during GCP inspections. These elements tend to receive insufficient resources during active enrollment, as site staff focuses primarily on recruitment and logistical tasks related to visits.
- Treating GCP as a one-time milestone rather than an ongoing requirement can lead to compliance issues. It’s often noted during inspections that strong compliance at the start of a trial deteriorates over time. GCP must be actively maintained, monitored, and documented throughout the entire duration of the study, not just at its initiation.
Germany is not inherently difficult for running trials, but it is unforgiving for sponsors who approach it as merely “European.” Experienced authorities and a well-defined process mean the sponsors who succeed do so by investing early in complete and accurately translated documentation, understanding the dual-track approval structure, and embedding GCP compliance into daily operations rather than implementing it only upon inspection announcements.
Zenovel assists sponsors conducting clinical trials in Germany by preparing complete and accurately translated CTIS submissions and ensuring audit-ready GCP documentation throughout the trial lifecycle. Our team assists sponsors with BfArM and PEI submissions, coordinates with ethics committees, and ensures inspection readiness, facilitating timely trial progress in compliance with German and EU regulations. For further information on how Zenovel can assist your trial in Germany, please visit our website.
